• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Thermo Fisher Scientific Invests to Enhance U.S. Innovation and Support Customers' Manufacturing

    4/24/25 8:00:00 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials
    Get the next $TMO alert in real time by email

    Investment demonstrates confidence in America's commitment to science and innovation

    Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, will invest an additional $2 billion in the United States over the next four years, strengthening American innovation, manufacturing and economic competitiveness across the life sciences sector.

    As one of the largest manufacturers of medicines in the world, Thermo Fisher enables biopharma companies to develop and produce their medicines in America. These additional investments to the company's American manufacturing capacity support a resilient U.S. healthcare supply chain and will have a strong multiplier effect across the American economy.

    The $2 billion investment over the next four years includes:

    • $1.5 billion in capital expenditures to enhance and expand U.S. manufacturing operations
    • Complemented by $500 million in R&D focused on high-impact innovation

    "Thermo Fisher's commitment to U.S. manufacturing reflects our confidence that America will continue to lead the world in science and innovation. Thermo Fisher is proud to serve as a growth engine for the American economy," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. "By expanding our U.S. operations, we ensure that life-saving medicines and therapies will continue to be developed and produced in America for decades to come."

    This investment builds on Thermo Fisher's industry-leading foundation in U.S. manufacturing and innovation. The company has 64 U.S. manufacturing operations, located in 37 states, making analytical instruments, specialty diagnostics and life sciences solutions, as well as providing contract development and manufacturing services for pharmaceutical innovators.

    Since 2017, Thermo Fisher has more than doubled in size—from $21 billion in revenue and 28,000 U.S. employees to $43 billion in revenue and more than 50,000 U.S. employees today. The company also invests $1 billion annually in R&D in the U.S. Over the next four years, the company will continue to expand its impact in the U.S. by creating high-paying jobs, adding manufacturing and lab services capacity, and investing in research and development.

    About Thermo Fisher Scientific

    Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

    Safe Harbor Statement

    The following constitutes a "Safe Harbor" statement under the Private Securities Litigation Reform

    Act of 1995: This press release contains forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general economic conditions and related uncertainties; dependence on customers' capital spending policies and government funding policies; the effect of economic and political conditions and exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations; any natural disaster, public health crisis or other catastrophic event; and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to recent or pending acquisitions, may not materialize as expected. Additional important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in our most recent annual report on Form 10-K, which is on file with the SEC and available in the "Investors" section of our website under the heading "SEC Filings." While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if estimates change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250424389005/en/

    Media Contact Information:

    Sandy Pound

    Phone: 781-622-1223

    E-mail: [email protected]

    Website: www.thermofisher.com

    Investor Contact Information:

    Rafael Tejada

    Phone: 781-622-1356

    E-mail: [email protected]

    Get the next $TMO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TMO

    DatePrice TargetRatingAnalyst
    12/11/2025$660.00Neutral → Buy
    Citigroup
    12/9/2025$685.00Buy
    Goldman
    12/8/2025$750.00Sector Weight → Overweight
    KeyBanc Capital Markets
    12/2/2025$670.00Overweight
    Morgan Stanley
    12/1/2025$670.00Hold → Buy
    HSBC Securities
    9/11/2025$550.00Equal Weight → Overweight
    Barclays
    8/19/2025Outperform
    William Blair
    7/24/2025$510.00Buy → Hold
    HSBC Securities
    More analyst ratings

    $TMO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Vice President Pettiti Gianluca sold $216,480 worth of shares (400 units at $541.20), decreasing direct ownership by 2% to 20,752 units (SEC Form 4)

    4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

    2/11/26 4:26:42 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    SEC Form 4 filed by Director Lynch Karen S

    4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

    1/5/26 5:13:12 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    SEC Form 4 filed by Director Keith R. Alexandra

    4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

    1/5/26 5:10:10 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    $TMO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Thermo Fisher Scientific Increases Quarterly Dividend

    Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.47 per common share, payable on April 15, 2026, to shareholders of record as of March 13, 2026. This reflects a 10% increase over the previous dividend payment of $0.43. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in thei

    2/25/26 4:15:00 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Thermo Fisher Scientific to Present at Raymond James Annual Institutional Investors Conference

      Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Raymond James Institutional Investors Conference on Tuesday, March 3, 2026, at 9:15 a.m. (ET). A live webcast of the presentation will be available in the Investors section of our website, www.thermofisher.com, with a replay accessible shortly after the presentation concludes. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether

    2/24/26 8:00:00 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Thermo Fisher Scientific Prices Offering of USD-Denominated Senior Notes

    Thermo Fisher Scientific Inc. (NYSE:TMO) ("Thermo Fisher") announced today that it has priced an offering of $3.8 billion aggregate principal amount (the "Offering") of the following notes: $1.0 billion aggregate principal amount of its 4.215% senior notes due 2031 (the "2031 notes") at the issue price of 100.000% of their principal amount; $750 million aggregate principal amount of its 4.550% senior notes due 2033 (the "2033 notes") at the issue price of 99.783% of their principal amount; $1.3 billion aggregate principal amount of its 4.902% senior notes due 2036 (the "2036 notes") at the issue price of 100.000% of their principal amount; and $750 million aggregate principal am

    2/9/26 9:41:00 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    $TMO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Thermo Fisher upgraded by Citigroup with a new price target

    Citigroup upgraded Thermo Fisher from Neutral to Buy and set a new price target of $660.00

    12/11/25 8:46:38 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Goldman initiated coverage on Thermo Fisher with a new price target

    Goldman initiated coverage of Thermo Fisher with a rating of Buy and set a new price target of $685.00

    12/9/25 8:54:23 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Thermo Fisher upgraded by KeyBanc Capital Markets with a new price target

    KeyBanc Capital Markets upgraded Thermo Fisher from Sector Weight to Overweight and set a new price target of $750.00

    12/8/25 8:17:51 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    $TMO
    SEC Filings

    View All

    Thermo Fisher Scientific Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)

    2/12/26 4:19:10 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    SEC Form 424B5 filed by Thermo Fisher Scientific Inc

    424B5 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)

    2/10/26 5:02:01 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    SEC Form FWP filed by Thermo Fisher Scientific Inc

    FWP - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)

    2/9/26 5:25:28 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    $TMO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Chai Nelson sold $8,449 worth of shares (16 units at $528.09) and bought $11,038 worth of shares (20 units at $551.90), increasing direct ownership by 0.03% to 14,252 units (SEC Form 4)

    4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

    2/21/25 4:19:32 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Boxer Michael A bought $2,105 worth of shares (4 units at $526.15), increasing direct ownership by 0.03% to 13,101 units (SEC Form 4)

    4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

    10/6/23 4:23:51 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    $TMO
    Financials

    Live finance-specific insights

    View All

    Thermo Fisher Scientific Increases Quarterly Dividend

    Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.47 per common share, payable on April 15, 2026, to shareholders of record as of March 13, 2026. This reflects a 10% increase over the previous dividend payment of $0.43. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in thei

    2/25/26 4:15:00 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2025 Results

    Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Full Year 2025 Highlights Fourth quarter revenue grew 7% to $12.21 billion. Fourth quarter GAAP diluted earnings per share (EPS) grew 9% to $5.21. Fourth quarter adjusted EPS grew 8% to $6.57. Full year revenue grew 4% to $44.56 billion. Full year GAAP diluted earnings per share (EPS) grew 7% to $17.74. Full year adjusted EPS grew 5% to $22.87. Delivered another year of excellent operational performance and share gain reflecting our active management of the company, the

    1/29/26 6:00:00 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, January 29, 2026

    Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, announced that it will release its financial results for the fourth quarter and full year 2025 before the market opens on Thursday, January 29, 2026, and will hold a conference call on the same day at 8:30 a.m. ET. During the call, the company will discuss its financial performance, as well as future expectations. The call will be webcast live on the "Investors" section of our website, www.thermofisher.com. You can access the conference call by dialing (833) 470-1428 within the U.S. or +1 (646) 844-6383 outside the U.S. The access code is 054943. The earnings press release and related information can also be fo

    12/26/25 8:00:00 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    $TMO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Thermo Fisher Scientific Inc (Amendment)

    SC 13G/A - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)

    2/9/23 11:35:13 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13G/A filed

    SC 13G/A - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)

    2/10/21 11:57:23 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    $TMO
    Leadership Updates

    Live Leadership Updates

    View All

    Henry Schein Names Frederick M. Lowery as Chief Executive Officer

    Industry veteran brings more than 20 years of healthcare distribution experience and operational excellence Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical professionals, today announced the appointment of Frederick M. Lowery as its new Chief Executive Officer ("CEO"), effective March 2, 2026, at which time he will join the Board of Directors. Mr. Lowery succeeds Stanley M. Bergman, who will step down as CEO after 35 years and continue to serve as Chairman of the Board to ensure a smooth and effective leadership transition. This press release features multimedia. View the full release here: https://www.businesswire

    1/12/26 7:00:00 AM ET
    $HSIC
    $TMO
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    Thermo Fisher Scientific's Chief Financial Officer, Stephen Williamson, to Retire in Early 2026

    Jim Meyer to Become Chief Financial Officer, Effective March 1, 2026 Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that Stephen Williamson, senior vice president and chief financial officer (CFO), has decided to retire from the company, effective March 31, 2026. The company's board of directors has approved the appointment of Jim Meyer, currently vice president of financial operations, to succeed Williamson as CFO, effective March 1, 2026. Williamson, age 58, has led Thermo Fisher's global finance organization as CFO since 2015. He joined the company in 2001 as Vice President, European Financial Operations. To ensure a seamless transition

    7/23/25 9:00:00 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials